within Pharmacolibrary.Drugs.ATC.B;

model B01AC17
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0035499999999999998,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.023,
    k12             = 217,
    k21             = 217
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC17</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tirofiban is a non-peptide, reversible inhibitor of the glycoprotein IIb/IIIa receptor on platelets, used as an antiplatelet agent to reduce thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) and during percutaneous coronary intervention (PCI). It is approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Théroux, P (1999). Tirofiban. <i>Drugs of today (Barcelona, Spain : 1998)</i> 35(1) 59–73. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12973410/&quot;>https://pubmed.ncbi.nlm.nih.gov/12973410</a></p></li><li><p>Kondo, K, &amp; Umemura, K (2002). Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. <i>Clinical pharmacokinetics</i> 41(3) 187–195. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241030-00003&quot;>10.2165/00003088-200241030-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11929319/&quot;>https://pubmed.ncbi.nlm.nih.gov/11929319</a></p></li><li><p>Liu, C, et al., &amp; Zi, W (2024). Effects of tirofiban on large vessel occlusion stroke are modified by etiology and renal function. <i>Annals of clinical and translational neurology</i> 11(3) 618–628. DOI:<a href=&quot;https://doi.org/10.1002/acn3.51982&quot;>10.1002/acn3.51982</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38156359/&quot;>https://pubmed.ncbi.nlm.nih.gov/38156359</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC17;
